Connect with us

BUSINESS

mCig Inc (OTCMKTS:MCIG) Amare’s SolarBar 800 System Outshines The Competitors In The Specialty Lighting of The US And Delivers 2.69J At 880W For Superior Yield

Published

on

Innovative SolarBar 800 system (Bar8) of mCig Inc (OTCMKTS:MCIG) has outshined the competitors in the specialty lighting of the US. The company is pleased with the favorable results for its new Amare LED lighting systems in the cannabis sector.

Chief Operating Officer of mCig, Victor Nguyen said the main aim of the company is to design a powerful, flexible, and efficient lighting solution, which offers high-quality yield for the production of commercial cannabis.

2.82J @484W

SolarBar800 uses an option of SolarSpec HO to deliver 2.79J @ 880W and 2.82J @ 484W. The top commercial growers witnessed excellent results in quality and yield using these innovative lighting solutions when compared to results of the 1000 W double ended models and LEDs of topnotch companies. Victor said the company is committed to innovation and Bar8 is a testimony to that commitment.

Features of Bar8

Bar8 is developed using sophisticated technology to deliver flexibility, power, and efficiency to the commercial growers. It is suitable for single and multi-tier commercial cultivation of cannabis. The product facilitates the change of height over a canopy of 6-60 inches. Its other features are detachable bars and a remote supply to enhance the yield and flowering footprint by 50% and 4′ x 6′. The dimensions of Bar8 are 47.08-inch x 46.93-inch x 3.3 inch.

mCig uses Meanwell driver and Osram or Samsung LEDs in these innovative Bar8 lighting systems. The 900 W version is dimmable to suit the lighting needs of the cultivation. Bar8 comes with a 5-year warranty.

mCig has launched a redesigned corporate website that provides information about its products and services to the clients and partners. Potential investors and shareholders will get the latest vision of mCig from the corporate website.

Chief Executive Officer of mCig, Paul Rosenberg said the launch of the revamped website is part of its efforts to stay on track that helped to maintain leadership in the cannabis market. The company has taken key decisions in recent weeks to improve its business outlook and enhance value for the shareholders. mCig is committed to meet the promises given to the shareholders on implementing the new initiatives.

BUSINESS

Kannaway, A Subsidiary Of Medical Marijuana Inc (OTCMKTS:MJNA), Is The Most Popular CBD MLM Company: Hemp Meds Mexico Inaugurates a New Office In Mexico

Published

on

Kannaway, a subsidiary of Medical Marijuana Inc (OTCMKTS:MJNA), has become the well known CBD MLM company in 2020. It finds a place in the HealthMJ’s list this year. Business for Home has listed Kannaway, one of the top hundred MLM companies in 2020.

Kannaway establishes quality standards

Blake Schroeder, Chief Executive Officer of Kannaway, said it is exciting to get recognition as a top player in the industry even today after becoming the first company to market the CBD products in 2014 directly. The enactment of a Farm Bill in 2018 helped the CBD industry to post remarkable growth in 2019. Kannaway played a vital role in 2019 in establishing several safety and quality standards for the market to flourish.

The US consumers learn about CBD from friends

Over 50% of the US consumers learned about cannabidiol for the first time from family and friends. The demand for hemp-based CBD in the US is expected to reach up to $2.75 billion in 2020. According to Direct Selling News, the sales of CBD related products by the direct selling companies are estimated at more than $300 million in 2018.

Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, said Kannaway is flourishing in the CBD market, which is growing at a fast pace. He further said the company is excited to get honored on HealthMJ’s list and among the top 100 MLM companies in 2020. The company also bagged several accolades that include BIG Awards for Business, Stevie Awards, and Golden Bridge Awards. It is yearning to receive more such awards this year.

HempMeds Mexico inaugurates new office

HempMeds Mexico, a subsidiary of Medical Marijuana, has inaugurated a new office in Mexico City. President of HempMeds Mexico, Raul Elizalde, said the company is pleased to establish a new office, and it helps to strengthen its footprint in the nation. It is already managing offices in Monterrey since 2017. The newly opened office will help the public with a plethora of information on CBD products being offered in Mexico.

The market for the medical cannabis market

The market for medical cannabis in Mexico in 2018 is estimated at $47.3 million. If cannabis for recreational and medical uses is legalized, the combined demand for medical and recreational use will reach over $1 billion by the year 2024.

Continue Reading

BUSINESS

Sundial Growers Inc (NASDAQ:SNDL) And Vir Biotechnology Inc (NASDAQ:VIR) Strike Deal To Support Clinical Studies

Published

on

Sundial Growers Inc (NASDAQ:SNDL) and Vir Biotechnology Inc (NASDAQ:VIR) are into a new deal that spans about three years. The terms of the deal outline that Sundial will be serving Vir Pharma with medical cannabis oil supplies.

The business cooperation

On the other hand, Vir Pharma intends to make an impact in the treatment of chronic pain and will be using products from the business partner. The plan is to conduct its clinical studies effectively in Australia, and the oral formulations will be used in the development of its prescription drug.

The proprietary drug will be developed using cannabis products, and the company is optimistic patients will benefit from the medication. It will be about giving them a break from the use of the various treatments developed using opioids.

Thoughts from leaders

The Chief Operating Officer of Sundial, known as Brian Harriman, is one of the leaders that have spoken concerning the matter. The official has termed the recent move an outstanding one considering that it is about them triumphant entry into Australia. It also marks the company’s first global exports, and the official believes that they are taking steps in the right direction.

The leader also thinks quite highly about their business partner calling it one of the leading companies in the market. He believes that it is such a great honor getting the opportunity to work with Vir Pharma on their quest to grasp business leadership. Harriman also says that the patients in Australia deserve the best form of treatment, and it is a good thing that they will be receiving the top quality cannabis-based therapies.

The terms of this deal also provide that the cannabis blend developed by the two will be marketed under Vir Pharma’s label, and the brand name will be Virabis.

The CEO of Vir Pharma Joel Hardy has also spoken on behalf of his company, outlining that they are proud to be a part of the companies focusing on developing cannabis medicines. According to him, these full-spectrum medicines are essential in helping to eliminate or minimize the use of opioid products as a form of treatment. He says that he will be at the frontline in supporting the cooperation between the two companies.

Continue Reading

BUSINESS

Amyris Inc (NASDAQ:AMRS) Completes The Shipment Of First Cannabinoids To LAVVAN: Gearing To Ship Second Cannabioid Shipment In H1 2020

Published

on

Amyris Inc (NASDAQ:AMRS) has completed the first shipment of cannabinoids to its associate – LAVVAN. The company is also gearing to meet the second shipment of cannabinoids in H1 2020. It has developed the ingredients using its fermentation technology platform. The company is maintaining high purity and quality when compared to the ingredients derived from cannabis plants.

A leader in natural ingredients

Amyris uses its proprietary technology to scale the ingredients.  The company is a leader in extracting the natural and clean beauty ingredients using fermentation. It also entered a pact with a leading pharmaceutical company in Asia to develop and target oncology treatment. Amyris also signed a pact with its partner in China for vitamins.

Committed to delivering the highest purity ingredients

Chief Executive Officer and President of Amyris, John Melo, said the company is pleased to close the year 2019 with significant progress in business and operational performance. The company expects to maintain its leadership by delivering the highest purity ingredients for beauty, health, fragrance, and flavor industries. Amyris expects to report a strong quarter by delivering leading products.

Amyris posted record production in Q4 2019; its clean beauty business is also delivering better than expected performance. The company is satisfying the strong consumer and market demand for natural and clean products. John said its team reported excellent production and shipment volumes. The team helped to deliver high-quality renewable products to the consumers.

Amyris started 2020 with excellent performance. It expects to double the sales this year, especially after posting better performance in Clean Beauty. The company already posted a 190% growth in the first 12 days of this month after reporting strong Biossance results in January 2019.

John further said the company benefitted from its technological advantage and reputation to scale up products and achieve commercial success. It formed a basis to apply for intellectual property and mobilize funds for the business. The company is celebrating the commercial success of its first cannabinoids.

Amyris introduces PURECANE Brand sweetener

Amyris has introduced PURECANE brand sweetener online for the consumer to make immediate purchases. It is great news for health-conscious consumers to enjoy sweet indulgences.

Continue Reading



Trending Stories